BioSpace News Archive

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), today announced that it has expanded its ongoing Phase 1b/2 trial of BXCL701, the Company’s investigational, orally administered innate immune activator, in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients with either de novo or treatment-emergent small-cell neuroendocrine carcinoma (SCNC).

Cullinan Oncology, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted and immuno-oncology therapies, announced the appointment of Nadim Ahmed as President and Chief Executive Officer.

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced it will host the first in a series of Key Opinion Leader (KOL) events on the emerging atopic dermatitis treatment landscape.

Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference

Immunocore (Nasdaq: IMCR), and Medison Pharma Ltd., today announced an exclusive multi-regional agreement for Medison to help seek regulatory authorization and commercialize Immunocore’s tebentafusp (IMCgp100).

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.

Blade Therapeutics, Inc. (Blade or the company), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the initiation of a phase 1 drug-drug interaction clinical study of cudetaxestat.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today the enrollment of the first patient in the US in its Phase IIb clinical trial with vafidemstat, a selective inhibitor of the epigenetic target LSD1, in Borderline Personality Disorder (BPD) patients.

CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced a license and collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors.

Encodia , a privately held biotech company developing next-generation solutions for proteomics research, announced the hiring of Nigel Beard, Ph.D., as Chief Technology Officer (CTO).